ALS News Today

October 23, 2020October 23, 2020

Catalent to Produce BrainStorm’s NurOwn Cell Therapy for ALS

ALS News Today

Catalent Biologics has agreed to manufacture NurOwn, the cell-based therapy by BrainStorm Cell Therapeutics being evaluated in a soon-to-conclude pivotal trial as a possible treatment of amyotrophic lateral sclerosis (ALS). With this ... Read more

October 23, 2020October 23, 2020

Telehealth ‘Helpful’ Alternative to In-person Care, Rare Disease Patients Say

ALS News Today, COVID-19 News

A majority of rare disease patients using telehealth during the COVID-19 pandemic thought the experience positive, and many would like the option of continuing its use in future appointments, a series ... Read more

October 22, 2020October 22, 2020

Pivotal Trial Testing Multiple Therapies in ALS Now Enrolling at Third Scotland Site

ALS News Today, COVID-19 News

MND-SMART, a pivotal platform trial designed to simultaneously test multiple treatment candidates in people with amyotrophic lateral sclerosis (ALS) and other motor neuron diseases, has opened its third clinical site ... Read more

October 21, 2020October 21, 2020

$2M NIH Grant Supports Work Into Cell Structures Linked to ALS Protein Clumps

ALS News Today

A $2 million grant from the National Institutes of Health (NIH) is funding work to better understand how molecular structures called protein-RNA condensates form and are regulated within cells. Findings ... Read more

October 20, 2020October 20, 2020

Study Identifies Environmental Risk Factors for Developing ALS

ALS News Today

Head trauma, electrical burns, and hobbies involving the toxic metal lead appear to be risk factors for developing amyotrophic lateral sclerosis (ALS), a U.S.-based study found. Holding a job in ... Read more

October 19, 2020October 19, 2020

AMX0035 Significantly Extends ALS Patients’ Lives, Long-term Data Show

ALS News Today

Treatment with AMX0035, Amylyx’s experimental oral therapy, significantly extends the lives of amyotrophic lateral sclerosis (ALS) patients with rapidly progressing disease, according to a long-term survival analysis of the CENTAUR ... Read more

October 16, 2020October 16, 2020

Activities and Events Underway for AAC Awareness Month

ALS News Today

October is International Augmentative and Alternative Communication (AAC) Awareness Month, set aside annually to inform the public about how amyotrophic lateral sclerosis (ALS) patients and others use these devices to communicate. ... Read more

October 15, 2020October 15, 2020

€1 Million Contest Seeks to Improve Functionality in ALS

ALS News Today

With a €1 million (about $1.1 million) prize being offered, researchers are invited to join a challenge that seeks to give people with motor neuron diseases (MND) – including those ... Read more

October 14, 2020October 14, 2020

Nerve Injury Progressing in Top-down Manner Evident in Bulbar ALS

ALS News Today

Most people with bulbar onset amyotrophic lateral sclerosis (ALS) showed distinct signs of motor neuron injury starting in the bulbar region of the brain that controls swallowing and speaking, before ... Read more

October 13, 2020October 13, 2020

Phase 2 Study of Pegcetacoplan in Recently Diagnosed Patients Opens

ALS News Today

A Phase 2 and potentially pivotal study investigating pegcetacoplan (APL-2) as a potential treatment for amyotrophic lateral sclerosis (ALS) is now enrolling patients, Apellis Pharmaceuticals, the therapy’s developer, announced in a press ... Read more

October 12, 2020October 12, 2020

BrainStorm Details Phase 3 Trial Design of NurOwn for Rapidly Progressing ALS

ALS News Today

BrainStorm Cell Therapeutics is sharing the details of the design of its Phase 3 clinical trial evaluating NurOwn as a treatment for people with rapidly progressing amyotrophic lateral sclerosis (ALS), ... Read more

October 9, 2020October 9, 2020

Libra Therapeutics Launches With Pipeline of 3 ALS Treatment Candidates

ALS News Today

Libra Therapeutics has officially announced its launch with a platform dedicated to developing new treatments for neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The company also has ... Read more

October 8, 2020October 8, 2020

Scribe, Biogen Partner to Develop Gene Therapy for ALS, Other Neurological Diseases

ALS News Today

Scribe Therapeutics and Biogen, a biotechnology company focused on neurological diseases, have established a research partnership to develop new gene therapies for amyotrophic lateral sclerosis (ALS) using the gene-editing technology CRISPR-Cas9. ... Read more

October 7, 2020October 7, 2020

MDA Issues $1.6M in Grants to Boost ALS Research

ALS News Today

The Muscular Dystrophy Association (MDA) has awarded five new grants totaling more than $1.6 million to boost research of amyotrophic lateral sclerosis (ALS). These grants add to the $168 million already ... Read more

October 5, 2020October 5, 2020

Target ALS, Spartan Team Up on ‘The Toughest Challenge’ for ALS Research

ALS News Today, COVID-19 News

Target ALS is teaming up with Spartan on a global initiative to raise funds for research that will contribute to the fight against amyotrophic lateral sclerosis (ALS). Called “The Toughest ... Read more